CLINICAL TRIALS PROFILE FOR FETZIMA
✉ Email this page to a colleague
All Clinical Trials for FETZIMA
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT02265367 ↗ | Novel Medication as a Potential Smoking Cessation Aid | Completed | University of Minnesota | Early Phase 1 | 2015-01-01 | The purpose of this study is to provide preliminary information assessing if levomilnacipran may be effective at increasing smoking cessation rates. |
NCT02265367 ↗ | Novel Medication as a Potential Smoking Cessation Aid | Completed | University of Minnesota - Clinical and Translational Science Institute | Early Phase 1 | 2015-01-01 | The purpose of this study is to provide preliminary information assessing if levomilnacipran may be effective at increasing smoking cessation rates. |
NCT02288325 ↗ | A Multicenter, Relapse Prevention Study With Levomilnacipran Extended Release (ER) in Participants With Major Depressive Disorder | Completed | Forest Laboratories | Phase 4 | 2014-11-18 | This study evaluates the efficacy, safety and tolerability of levomilnacipran extended-release (ER) compared with placebo in the prevention of depression relapse in major depressive disorder (MDD). |
NCT02431806 ↗ | Safety and Efficacy of Levomilnacipran ER in Adolescent Participants With Major Depressive Disorder | Completed | Forest Laboratories | Phase 3 | 2015-06-23 | The purpose of this study is to evaluate the efficacy, safety, and tolerability of levomilnacipran ER relative to placebo in adolescent outpatients (12-17 years) with Major Depressive Disorder (MDD). In addition, the study is designed to obtain pharmacokinetics (PK) data to guide dose selection for future pediatric studies of levomilnacipran. |
NCT02466958 ↗ | Trial of Levomilnacipran in Geriatric Depression | Completed | University of California, Los Angeles | Phase 4 | 2016-06-01 | The purpose of this study is to examine the effects of levomilnacipran (FETZIMA) compared to placebo for the treatment of depression in older adults. |
NCT02720198 ↗ | Levomilnacipran ER vs. Adjunctive Quetiapine for Adults With Inadequate Relief With SSRIs in MDD | Completed | Forest Laboratories | Phase 3 | 2017-01-23 | This study's primary objective is to compare the efficacy and tolerability of switching patients with inadequate relief on generic SSRIs to levomilnacipran versus adding a new treatment (quetiapine) to the participants' existing treatment with people diagnosed with depression (major depression disorder). The secondary objective is to examine the response and remission rates following the switch from a generic SSRI to levomilnacipran ER and augmentation with quetiapine along with examining changes in neurocognitive and apathy measures after the switch. |
NCT02720198 ↗ | Levomilnacipran ER vs. Adjunctive Quetiapine for Adults With Inadequate Relief With SSRIs in MDD | Completed | Institute for Advanced Medical Research, Alpharetta, GA | Phase 3 | 2017-01-23 | This study's primary objective is to compare the efficacy and tolerability of switching patients with inadequate relief on generic SSRIs to levomilnacipran versus adding a new treatment (quetiapine) to the participants' existing treatment with people diagnosed with depression (major depression disorder). The secondary objective is to examine the response and remission rates following the switch from a generic SSRI to levomilnacipran ER and augmentation with quetiapine along with examining changes in neurocognitive and apathy measures after the switch. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for FETZIMA
Condition Name
Clinical Trial Locations for FETZIMA
Trials by Country
Clinical Trial Progress for FETZIMA
Clinical Trial Phase
Clinical Trial Sponsors for FETZIMA
Sponsor Name